Research programme: protein tyrosine phosphatase inhibitors - Metabasis Therapeutics

Drug Profile

Research programme: protein tyrosine phosphatase inhibitors - Metabasis Therapeutics

Latest Information Update: 13 Nov 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cengent Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 29 Jun 2006 Metabasis Therapeutics acquired from Cengent's note holders all of the assets of Cengent pertaining to PTP-1B programme for metabolic diseases
  • 04 Sep 2003 Preclinical data from a media release have been added to the Diabetes pharmacodynamics section
  • 26 May 2003 The programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top